A new study published Thursday found that groundbreaking weight loss and diabetes medications also combat opioid-use disorder and alcohol misuse disorder.

This is the second study this fall to suggest that GLP-1s, such as Novo Nordisk’s Ozempic and Wegovy or Eli Lilly’s Mounjaro and Zepbound, have the ability to revolutionize the drug treatment options for people addicted to drugs or alcohol.